The Patent Finder

Theta Biomedical Consulting & Development Co., Inc.

Also on record
Records under this name other than the patents Theta Biomedical Consulting & Development Co., Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.

Back to Theta Biomedical Consulting & Development Co., Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,759,307Compositions for protection against superficial vasodilator flush syndrome, and methods of use
Term ended
Term ended Nov 5, 2025 · USPTO record
Term endedTerm ended Nov 5, 2025USPTO record
US 7,923,043Method for protecting humans against superficial vasodilator flush syndrome
Lapsed on the fee record
Ended Apr 12, 2023 · USPTO record
Lapsed on the fee recordEnded Apr 12, 2023USPTO record
US 6,689,748Method of treating mast cell activation-induced diseases with a proteoglycan
Term ended
Term ended May 3, 2020 · USPTO record
Term endedTerm ended May 3, 2020USPTO record
US 7,115,278Proteoglycan compositions for the treatment of cardiovascular inflammatory diseases
Term ended
Term ended Sep 2, 2019 · USPTO record
Term endedTerm ended Sep 2, 2019USPTO record
US 6,984,667Synergistic proteoglycan compositions for inflammatory conditions
Term ended
Term ended Oct 8, 2018 · USPTO record
Term endedTerm ended Oct 8, 2018USPTO record
US 6,645,482Proteoglycan compositions for treating arthritic inflammatory conditions
Term ended
Ended no later than May 22, 2018 · USPTO record
Term endedEnded no later than May 22, 2018USPTO record
US 6,641,806Proteoglycan compositions for treating arthritic inflammatory conditions
Term ended
Ended no later than May 15, 2018 · USPTO record
Term endedEnded no later than May 15, 2018USPTO record
US 6,635,625Proteoglycan compositions for treating prostate and bladder inflammatory conditions
Term ended
Ended no later than May 1, 2018 · USPTO record
Term endedEnded no later than May 1, 2018USPTO record
US 6,624,148Proteoglycan compositions for treatment of cardiovascular inflammatory diseases
Term ended
Ended no later than Apr 8, 2018 · USPTO record
Term endedEnded no later than Apr 8, 2018USPTO record
US 7,906,153Anti-inflammatory compositions for treating multiple sclerosis
Term ended
Ended no later than Apr 8, 2018 · USPTO record
Term endedEnded no later than Apr 8, 2018USPTO record
10 of 17 patents shown.
Pro members see all 17.
Pro members: see all 17 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited